...
首页> 外文期刊>Journal of Clinical Microbiology >Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay
【24h】

Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay

机译:Xpert MTB / RIF分析的分析性能评估

获取原文
   

获取外文期刊封面封底 >>

       

摘要

We performed the first studies of analytic sensitivity, analytic specificity, and dynamic range for the new Xpert MTB/RIF assay, a nucleic acid amplification-based diagnostic system that detects Mycobacterium tuberculosis and rifampin (RIF) resistance in under 2 h. The sensitivity of the assay was tested with 79 phylogenetically and geographically diverse M. tuberculosis isolates, including 42 drug-susceptible isolates and 37 RIF-resistant isolates containing 13 different rpoB mutations or mutation combinations. The specificity of the assay was tested with 89 nontuberculosis bacteria, fungi, and viruses. The Xpert MTB/RIF assay correctly identified all 79 M. tuberculosis isolates and correctly excluded all 89 nontuberculosis isolates. RIF resistance was correctly identified in all 37 resistant isolates and in none of the 42 susceptible isolates. Dynamic range was assessed by adding 102 to 107 CFU of M. tuberculosis into M. tuberculosis-negative sputum samples. The assay showed a log-linear relationship between cycle threshold and input CFU over the entire concentration range. Resistance detection in the presence of different mixtures of RIF-resistant and RIF-susceptible DNA was assessed. Resistance detection was dependent on the particular mutation and required between 65% and 100% mutant DNA to be present in the sample for 95% certainty of resistance detection. Finally, we studied whether assay specificity could be affected by cross-contaminating amplicons generated by the GenoType MTBDRplus assay. M. tuberculosis was not detected until at least 108 copies of an MTBDRplus amplicon were spiked into 1 ml of sputum, suggesting that false-positive results would be unlikely to occur.
机译:我们对新的Xpert MTB / RIF分析进行了首次分析敏感性,分析特异性和动态范围的研究,Xpert MTB / RIF分析是一种基于核酸扩增的诊断系统,可检测结核分枝杆菌和利福平(RIF)的耐药性。 2小时内用79个系统发生和地理上不同的 M测试了该测定方法的敏感性。结核病分离株,包括42种药物敏感株和37种RIF耐药株,其中包含13种不同的 rpoB 突变或突变组合。用89种非结核菌,真菌和病毒测试了测定的特异性。 Xpert MTB / RIF分析正确鉴定了所有79个 M。结核菌分离株,并正确排除了所有89株非结核菌。在所有37个耐药菌株中和42个易感菌株中均未正确鉴定出RIF耐药性。通过将10 2 添加到 M的10 7 CFU中来评估动态范围。结核变成 M。结核阴性痰标本。该测定显示了在整个浓度范围内循环阈值和输入CFU之间的对数线性关系。评估了在RIF抗性和RIF易感性DNA的不同混合物存在下的抗性检测。抗药性检测取决于特定的突变,需要95%至100%的突变DNA才能存在于样品中,以确保95%的抗药性检测。最后,我们研究了GenoType MTBDRplus分析产生的交叉污染扩增子是否会影响分析特异性。 M。在将至少10 8 份MTBDRplus扩增子掺入1 ml痰液中之前,未检测到结核病。这表明不太可能发生假阳性结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号